Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

525 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration.
Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland ML, Tarp U, van Riel PL, Nordström DC, Gomez-Reino J, Pavelka K, Tomsic M, Kvien TK, van Vollenhoven RF, Gabay C. Chatzidionysiou K, et al. Among authors: nasonov e. Ann Rheum Dis. 2012 Mar;71(3):374-7. doi: 10.1136/annrheumdis-2011-200003. Epub 2011 Oct 4. Ann Rheum Dis. 2012. PMID: 21972242
Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries.
Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland ML, Tarp U, Gabay C, van Riel PL, Nordström DC, Gomez-Reino J, Pavelka K, Tomsic M, Kvien TK, van Vollenhoven RF. Chatzidionysiou K, et al. Among authors: nasonov e. Ann Rheum Dis. 2011 Sep;70(9):1575-80. doi: 10.1136/ard.2010.148759. Epub 2011 May 12. Ann Rheum Dis. 2011. PMID: 21571731
Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration.
Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland ML, Tarp U, Ancuta I, Pavelka K, Nordström DC, Gabay C, Canhão H, Tomsic M, van Riel PL, Gomez-Reino J, Kvien TK, van Vollenhoven RF; Rheumatic Diseases Portuguese Register. Chatzidionysiou K, et al. Among authors: nasonov e. Arthritis Res Ther. 2016 Feb 16;18:50. doi: 10.1186/s13075-016-0951-z. Arthritis Res Ther. 2016. PMID: 26883119 Free PMC article.
Erratum to: Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration.
Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland ML, Tarp U, Ancuta I, Pavelka K, Nordström DC, Gabay C, Canhão H, Tomsic M, van Riel PL, Gomez-Reino J, Kvien TK, van Vollenhoven RF. Chatzidionysiou K, et al. Among authors: nasonov e. Arthritis Res Ther. 2016 Jun 20;18(1):144. doi: 10.1186/s13075-016-1048-4. Arthritis Res Ther. 2016. PMID: 27324256 Free PMC article. No abstract available.
Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study.
Genovese MC, McKay JD, Nasonov EL, Mysler EF, da Silva NA, Alecock E, Woodworth T, Gomez-Reino JJ. Genovese MC, et al. Among authors: nasonov el. Arthritis Rheum. 2008 Oct;58(10):2968-80. doi: 10.1002/art.23940. Arthritis Rheum. 2008. PMID: 18821691 Free article. Clinical Trial.
Maintenance of remission with combination etanercept-DMARD therapy versus DMARDs alone in active rheumatoid arthritis: results of an international treat-to-target study conducted in regions with limited biologic access.
Pavelka K, Akkoç N, Al-Maini M, Zerbini CAF, Karateev DE, Nasonov EL, Rahman MU, Pedersen R, Dinh A, Shen Q, Vasilescu R, Kotak S, Mahgoub E, Vlahos B. Pavelka K, et al. Among authors: nasonov el. Rheumatol Int. 2017 Sep;37(9):1469-1479. doi: 10.1007/s00296-017-3749-7. Epub 2017 Jun 9. Rheumatol Int. 2017. PMID: 28597306 Clinical Trial.
Induction of response with etanercept-methotrexate therapy in patients with moderately active rheumatoid arthritis in Central and Eastern Europe in the PRESERVE study.
Pavelka K, Szekanecz Z, Damjanov N, Majdan M, Nasonov E, Mazurov V, Fabo T, Bananis E, Jones H, Szumski A, Tang B, Kotak S, Koenig AS, Vasilescu R. Pavelka K, et al. Among authors: nasonov e. Clin Rheumatol. 2013 Sep;32(9):1275-81. doi: 10.1007/s10067-013-2240-4. Epub 2013 May 11. Clin Rheumatol. 2013. PMID: 23666316 Clinical Trial.
Oral administration of GLPG0259, an inhibitor of MAPKAPK5, a new target for the treatment of rheumatoid arthritis: a phase II, randomised, double-blind, placebo-controlled, multicentre trial.
Westhovens R, Keyser FD, Rekalov D, Nasonov EL, Beetens J, Van der Aa A, Wigerinck P, Namour F, Vanhoutte F, Durez P. Westhovens R, et al. Ann Rheum Dis. 2013 May;72(5):741-4. doi: 10.1136/annrheumdis-2012-202221. Epub 2012 Nov 17. Ann Rheum Dis. 2013. PMID: 23161899 Clinical Trial.
Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial.
Ritchlin C, Rahman P, Kavanaugh A, McInnes IB, Puig L, Li S, Wang Y, Shen YK, Doyle MK, Mendelsohn AM, Gottlieb AB; PSUMMIT 2 Study Group. Ritchlin C, et al. Ann Rheum Dis. 2014 Jun;73(6):990-9. doi: 10.1136/annrheumdis-2013-204655. Epub 2014 Jan 30. Ann Rheum Dis. 2014. PMID: 24482301 Free PMC article. Clinical Trial.
525 results